Fig. 1From: Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy a & b Showing comparable Geometric mean titers for anti–HPV-16/18 at month 7 in 3 immunogenicity studies Africa [14], India [20] and Europe [24] across the age strata. In the vaccine groups for all the three studies, seropositivity to anti-HPV-16/18 was 100 % in initially seronegative participantsBack to article page